Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Smart Cells is a private healthcare company focused on the collection, processing, cryopreservation, and long-term storage of umbilical cord blood and cord tissue stem cells for family use. Founded in the UK in 2000, it markets itself as the UK’s first private cord blood stem cell storage company and operates internationally across the UK, Middle East, Hong Kong, and partner markets. The company generates revenue from stem cell banking services rather than from a traditional drug-development pipeline, although it positions its stored cell products as potential inputs for established transplant use and emerging regenerative medicine applications. In 2021, Smart Cells became part of the FamiCord Group after FamiCord acquired a majority stake in Smart Cells Holdings Limited. The business is commercial-stage and serves expectant families, healthcare professionals, and hospitals involved in maternity and stem cell collection services.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Smart Cells International.